MENU

News | CellFree Sciences

header jp

header en

News

CellFree Sciences Co., Ltd. received support from Ehime Prefecture under the "Ehime Prefecture New Growth Manufacturing Company Comprehensive Support Program in FY2021".

Category: Press releases Created: Friday, 30 July 2021

 

We are grateful, that Ehime Prefecture selected an application by CellFree Sciences under their "Ehime Prefecture New Growth Manufacturing Company Comprehensive Support Program in FY2021".

 

 

Having access to a unique set of about 23,000 human full-length proteins, CellFree Sciences will apply their own technologies including a protein bead array platform to search for new drug targets and therapeutic concepts.

 

While about 10 to 15% of the human proteins could play a role in disease, presently only about 2% of the human proteins can be directly targeted by a drug. Hence, there is a clear need to expand the number of druggable proteins to develop new therapeutic concepts and to cover a wider range of disease. In this project, we will apply new concepts to target drug targets for proteolytic degradation utilizing E3 ligases. Having extensive knowledge on E3 ligases, it is hoped that utilizing E3 ligases will offer new leads allowing for targeted proteolysis of selected targets while having less side effects than other drug candidates.

 

Project period: July 5, 2021-February 28, 2022.

 

 


 

 


 

 

 

 

We will be at BIO Digital 2021

Category: Society & Exhibition Created: Wednesday, 16 June 2021

 CellFree Sciences will be at Bio Digital 2021 from June 10 to 18, 2021.

 Please visit us from Partnering system

 

We are looking forward to welcome you and to provide you with more information on the use of our protein expression products and services.

 

Dr. Yaeta Endo, Special University Professor Emeritus, received the Ehime News Paper's Award

Category: Press releases Created: Monday, 17 May 2021

Dr. Yaeta Endo, who is the Special University Professor Emeritus, received the Ehime News Paper’s Award for developing wheat germ cell free protein expression system.

 

愛媛新聞賞・スポーツ賞贈呈式 松山|愛媛新聞ONLINE (ehime-np.co.jp)

Youtube,  https://www.youtube.com/watch?v=08JeP1wlFIA

Changing procedures for kit manuals from May 10, 2021

Category: Announcements Created: Wednesday, 28 April 2021

Thank you very much indeed for working together with CellFree Sciences and using our cell-free protein expression system in your work.

CellFree Sciences wants to contribute to the global efforts to reduce paper usage. Therefore, we have decided to ship from May 10, 2021, all our reagents and kits without a printed manual.

 

All our manuals are available for download on our homepage and directions on how to access the manuals and other product related information will be attached to each shipment for guiding our customers.

 

If you have any questions on the use of our products or how to access the product manuals, please contact us.

We are happy to assist you and to send you a PDF version of our manuals.

 

Thank you for your understanding and support! We hope our customers will appreciate our efforts to reduce paper use by switching to paperless notes or keeping the number of printed pages to a minimum.

The GHIT Fund of Japan continues their support for the development of a malaria transmission-blocking vaccine.

Category: Announcements Created: Thursday, 01 April 2021

The GHIT Fund of Japan announced on March 31, 2021, their new investments to support global R&D projects for neglected tropical diseases. This includes new funding for a First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1.

 

CellFree Sciences is most grateful for the continuous support given by the GHIT Fund for the development of an AnAPN1-based malaria transmission-blocking vaccine! In a project led by Prof. Rhoel Dinglasan at the University of Florida, we had been working together for several years on the development of an optimized antigen focusing on the transmission-blocking domain in the AnAPN1 protein. With the new GHIT funding, we will now move this new antigen to clinical development in Gabon.

 

We are looking forward to working together with Ajinomoto Bio-Pharma Services, GeneDesign, the Centre de Recherches Médicales de Lambaréné (CERMEL), University of Tübingen and The University of Florida to make this important project successful. It is our hope that this vaccine will in the future contribute to better malaria control and eradication.

 

Link to GHIT press release:

 

Project description on GHIT Webpage:

 

 

 

CellFree Sciences responded to new State of Emergency in Japan

Category: Announcements Created: Wednesday, 03 February 2021

On February 2nd, 2021, the Government of Japan extended the Coronavirus State of Emergency for Tokyo, Osaka and eight other prefectures for one more month. The new measures will be in effect until March 7th, 2021 according to the present government plans.

 

CellFree Sciences is fully supporting the actions of the Japanese Government! We have therefore extended also our own actions to protect our staff following government directions and to make our contribution to help stopping the further spread of the virus.

 

We will keep on making best efforts to support our customers also during the State of Emergency.

 

All orders will be processed as usual as we know about the importance of the work our customers are doing.

 

Please contact us for more information.

Outlook for 2021 from CellFree Sciences

Category: Articles Created: Tuesday, 02 February 2021

Our outlook for 2021 written by Ozawa, the President and CEO of CellFree Sciences Co., Ltd., was published on the international industry journal MED TECH Outlook.

 

Please click here for details.

A set of 1118 human transcription factors was made by our expression system to study side effects of "thalidmide"

Category: Announcements Created: Friday, 22 January 2021

A joint effort by several universities and research institutes in Japan, including our strategic technology partners Dr. Satoshi Yamanaka and Professor Tatsuya Sawasaki at the Proteoscience Center of Ehime University, conducted a comprehensive study using a human protein array comprising 1,118 human transcription factors produced in our wheat germ cell-free protein expression system. Screening those proteins led to the discovery that thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.

 

Thalidmide was originally used as a sleeping drug for pregnant women but had caused terrible side effects. Later it was found that Thalidmide and its derivatives are potent drugs for treating leprosy and multiple myeloma. These are highly effective drugs that are now sold for about 1 trillion yen per year in the world for treatment of blood cancers such as multiple myeloma. However, these drugs require a strict safety management to avoid teratomas. The new finding reported here will help to develop better thalidmide derivatives that could avoid any risk for teratoma formation.

 

For details, please click here.

 

Please click here for a paper on this research.

 

 

CellFree Sciences responded to new State of Emergency in Japan

Category: Announcements Created: Friday, 08 January 2021

On January 7th, 2021, the Government of Japan declared the State of Emergency for Tokyo and the three neighboring prefectures of Kanagawa, Saitama and Chiba in response to claiming numbers of COVID-19 cases in the area. The new measures will be in effect until February 7th, 2021 according to the present government plans.

 

CellFree Sciences is fully supporting the actions of the Japanese Government! We have taken actions to protect our staff following government directions and to make our contribution to help stopping the further spread of the virus.

 

We will make best efforts to support our customers also during the State of Emergency. 

 

All orders will be processed as usual as we know about the importance of the work our customers are doing.

 

Please contact us for more information.

Season Greetings From CellFree Sciences

Category: Announcements Created: Monday, 21 December 2020

 

Season Greetings

From CellFree Sciences!

 

2020 Season Greetings 2

Our way of saying thank you.

With the year ending, we want to thank you for working together with CellFree Sciences and express our sincere wishes for the Seasons and a Happy, Healthy and Prosperous New Year!


This year had been complicated for all of us with life been very much dominated by the ongoing COVID-19 pandemic and the suffering it had broad to many people worldwide. But there is also hope in the times of the pandemic, which showed more than ever the importance of life sciences and the contribution we can make to bring the pandemic to an end. It fills us with pride that also our wheat germ cell-free expression system is used in the response to the COVID-19 pandemic to prepare viral proteins for research and the development and production of diagnostic products now available on the Japanese market. CellFree Sciences is committed to keep on supporting medical research and to work for better solutions in global health.


CellFree Sciences will start into 2021 with new products and services to further expand on the applications of our protein expression system:
・ The formation of disulfide bonds plays important roles in the correct folding of many proteins. Therefore, we developed new reaction conditions to better support the formation of disulfide bonds in our expression system. The new Disulfide Bond PLUS Expression Kit and Disulfide Bond Enhancer Enzyme Set will provide a human protein disulfide isomerase (PDI) and the oxidase Ero1α to catalyze the formation of disulfide bonds for yielding correctly folded and more active proteins.


・ Biotinylated proteins have become an important tool to conduct biochemical studies including applications like affinity-based purification and detection, binding studies and screening, or immunoassays. Working with the wheat germ cell-free expression system enables direct biotinylation during protein synthesis by adding the BirA biotin ligase. We will offer services for the preparation of mono-biotinylated proteins in the new year using this approach.
Working with mono-biotinylated proteins can be advantageous as compared to working with random biotinylation methods and therefore we hope our new services along with the new products for working with proteins having disulfide bonds will support our customers to extend their research and development activities.


We all at CellFree Sciences are looking forward to being at your service again in 2021 supporting your important projects with our reagents and services. Please contact us and let us know about your needs and requirements. It is our commitment to work for our customers and partners to make your projects successful.


With all the very best wishes for you and yours for a better New Year 2021 from all of us at CellFree Sciences!

 

Copyright © CellFree Sciences Co.,Ltd. All Rights Reserved. [login]

We use cookies to ensure you get the best experience. By using our website you agree to our Cookie Policy.